Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03216226 · ClinicalTrials.gov registry record · Phase 3
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
A Phase 3 study, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT03216226 is a Phase 3 study that has completed, run by Zealand Pharma. The registered enrollment target is 112 participants.
The verdict
NCT03216226, a Phase 3 study, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon\* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207
Interventions
- DRUG dasiglucagon
- DRUG GlucaGen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2018-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03216226
The ClinicalTrials.gov registry entry for NCT03216226 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dasiglucagon is the first listed.
NCT03216226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03216226 about?
NCT03216226 is a clinical study titled "A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus". The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon\* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. \*dasiglucago...
What is the current status of trial NCT03216226?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2017-06-28. Estimated completion is 2018-02-13.
What interventions are being tested in trial NCT03216226?
The interventions under investigation include: dasiglucagon (DRUG), GlucaGen (DRUG).
Who is sponsoring clinical trial NCT03216226?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.